Page 5 - Structural Heart News Today

/CNW/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024. Key...

THE NEW Montefiore Structural Heart Program at White Plains Hospital provides patients with the most advanced procedures for heart valve.

Emory Heart & Vascular reached a significant historic milestone, performing a Transcatheter Aortic Valve Replacement (TAVR) procedure on its 5,000th patient at the end of last year. Emorys history with the innovative, minimally invasive procedure goes back all the way to 2007, when it became the first site in Georgia (and one of the first in the nation) to perform it.

Edwards Lifesciences today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13...

Edwards Lifesciences (NYSE:EW) announced today that the FDA granted approval for its Evoque tricuspid valve replacement system.

Edwards Lifesciences received approval for its Evoque tricuspid valve replacement system, the first transcatheter therapy approved in the US for tricuspid regurgitation.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Edwards Lifesciences Corporation today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration approval...

Using plasma proteomics and other approaches, researchers detected circulating proteins robustly associated with AV hemodynamics and the risk for related hospitalization.

SCOTTSDALE, Ariz., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to inve...